Lonza Group stock holds steady as the Swiss maker expands its business

Lonza Group stock is tied to pharmaceuticals and biologics manufacturing, with the Swiss company serving drug makers worldwide. The shares trade in Zurich and the business remains centered on contract development and manufacturing.

Lonza Group (ISIN CH0013841017) is a Swiss life sciences company that supplies contract development and manufacturing services to the pharmaceutical industry. Its business spans biologics, small molecules, and specialized ingredients for drug developers and manufacturers.

Business model

Lonza Group focuses on outsourced manufacturing and development work, which makes recurring demand from drug companies central to its earnings profile. That structure gives the company exposure to long-cycle pharma investment decisions rather than consumer demand.

Market context

Lonza shares trade in Zurich and the company is commonly followed as a European healthcare and manufacturing name. For US investors, the company is part of the broader global contract development and manufacturing services theme, where capacity, quality standards, and customer retention matter more than headline product launches.

Representative product

A representative Lonza offering is its integrated biologics manufacturing platform, which supports clinical and commercial production for biopharma customers. That kind of service mix is the clearest way to understand the company: it sells regulated production capacity and technical expertise, not a single consumer brand.

Stock context

Lonza Group's shares trade on the SIX Swiss Exchange in Swiss francs. As of July 12, 2026, no live quote is included here.

Lonza Group fact box

• Company: Lonza Group Ltd.
• ISIN: CH0013841017
• Ticker: LONN
• Exchange: SIX Swiss Exchange
• Sector / Industry: Health Care / Life Sciences Tools & Services